Pembrolizumab has been shown to have significantly greater efficacy than platinum doublet chemotherapy as a first‐line treatment for advanced non‐small cell lung cancer (NSCLC) patients with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%.1 This evidence concerns the gene CD274 and neoplasm.